Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Varenicline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 known ✓ | P17787 | 10/20 | 0.71 |
| ▸ | CHRNA4 known ✓ | P43681 | 10/20 | 0.71 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.71 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.71 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.71 |
| ▸ | CHRNG | P07510 | 2/20 | 0.71 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.71 |
| ▸ | CHRND | Q07001 | 2/20 | 0.71 |
| ▸ | ESR1 | P03372 | 1/20 | 0.71 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.71 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.71 |
| ▸ | HTR3A | P46098 | 1/20 | 0.71 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Varenicline SCHEMBL29761222 | 1.00 | CHRNB2 (0.71) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL31413925 | 1.00 | CHRNB2 (0.71) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL29761223 | 1.00 | CHRNB2 (0.71) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL22323984 | 1.00 | CHRNB2 (0.71) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL224852 | 1.00 | CHRNB2 (0.71) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL23510345 | 0.88 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL137144 | 0.84 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL5959022 | 0.84 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL225687 | 0.84 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL29710884 | 0.84 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221968-A1 | TREATMENTS AND METHODS FOR INCREASING DOPAMINE | UNIV OXFORD INNOVATION LTD (GB) | 2025-07-10 | — | — | US | claimed |
| EP-4493171-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE | Zhang, Yanfeng C/o Oxford University Innovation Limited (GB) | 2025-01-22 | — | — | EP | claimed |
| WO-2023175357-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-09-21 | — | — | WO | claimed |
| US-20250221968-A1 | TREATMENTS AND METHODS FOR INCREASING DOPAMINE | UNIV OXFORD INNOVATION LTD (GB) | 2025-07-10 | — | — | US | disclosed |
| EP-4493171-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE | Zhang, Yanfeng C/o Oxford University Innovation Limited (GB) | 2025-01-22 | — | — | EP | disclosed |
| WO-2023175357-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-09-21 | — | — | WO | disclosed |
| US-20140060552-A1 | METHODS AND DEVICES FOR DELIVERY AND MONITORING OF TOBACCO, NICOTINE, OR OTHER SUBSTANCES | PLOOM, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2581375-A2 | IMPROVED METHODS FOR THE PREPARATION OF QUINOXALINE DERIVATIVES | Medichem, S.A. (ES) | 2013-04-17 | — | — | EP | disclosed |
| US-8187607-B2 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2012-05-29 | — | — | US | disclosed |
| US-20120004239-A1 | Process for Preparing Quinoxaline Derivatives | MEDICHEM, S.A. (ES) | 2012-01-05 | — | — | US | disclosed |
| US-20100129395-A1 | Hapten-carrier conjugates and uses thereof | CYTOS BIOTECHNOLOGY AG (CH) | 2010-05-27 | — | — | US | disclosed |
| CN-101693712-A | Method for synthesizing Varenicline intermediate 2, 3, 4, 5-tetralin-1, 5-methylene-hydrogen-benzoazepine | SHANGHAI RECORD PHARMACEUTICAL | 2010-04-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004239-A1 | Process for Preparing Quinoxaline Derivatives | CYP3A7, CYP3A5, COMT | CHRNB2 233/4885CHRNA4 84/4885CHRNB4 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.